{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T12:17:17Z","timestamp":1775477837378,"version":"3.50.1"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013221","name":"Razi Vaccine and Serum Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013221","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008257","name":"Tarbiat Modares University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008257","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.intimp.2021.107927","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T17:43:51Z","timestamp":1630950231000},"page":"107927","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Liposome-based nanocarriers loaded with anthrax lethal factor and armed with anti-CD19 VHH for effectively inhibiting MAPK pathway in B cells"],"prefix":"10.1016","volume":"100","author":[{"given":"S. Reza","family":"Banihashemi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Rahbarizadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Zavaran Hosseini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davoud","family":"Ahmadvand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahryar","family":"Khoshtinat Nikkhoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.intimp.2021.107927_b0005","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma","volume":"29","author":"Ruan","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2021.107927_b0010","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1200\/JCO.2016.71.1556","article-title":"Genomics of hairy cell leukemia","volume":"35","author":"Tiacci","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2021.107927_b0015","article-title":"World cancer report 2014","author":"Stewart","year":"2017","journal-title":"Health"},{"issue":"5","key":"10.1016\/j.intimp.2021.107927_b0020","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrc.2017.17","article-title":"Prospects for combining targeted and conventional cancer therapy with immunotherapy","volume":"17","author":"Gotwals","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.intimp.2021.107927_b0025","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrclinonc.2013.46","article-title":"Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors","volume":"10","author":"Kochenderfer","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.intimp.2021.107927_b0030","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1158\/2159-8290.CD-14-1518","article-title":"Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations","volume":"5","author":"Ahronian","year":"2015","journal-title":"Cancer Discovery"},{"issue":"6","key":"10.1016\/j.intimp.2021.107927_b0035","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/eci.12441","article-title":"The Ras\/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications","volume":"45","author":"Delire","year":"2015","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.intimp.2021.107927_b0040","first-page":"1601","article-title":"Plumbagin induces G2\/M arrest, apoptosis, and autophagy via p38 MAPK-and PI3K\/Akt\/mTOR-mediated pathways in human tongue squamous cell carcinoma cells","volume":"9","author":"Pan","year":"2015","journal-title":"Drug Design Dev. Therapy"},{"key":"10.1016\/j.intimp.2021.107927_b0045","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ejmech.2016.01.012","article-title":"PI3K\/Akt\/mTOR and Ras\/Raf\/MEK\/ERK signaling pathways inhibitors as anticancer agents: structural and pharmacological perspectives","volume":"109","author":"Asati","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.intimp.2021.107927_b0050","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1634\/theoncologist.2014-0465","article-title":"Targeting angiogenesis in cancer therapy: moving beyond vascular endothelial growth factor","volume":"20","author":"Zhao","year":"2015","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.intimp.2021.107927_b0055","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1006\/bbrc.1998.9040","article-title":"Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine\/threonine phosphorylation of MAPKs in cultured macrophages","volume":"248","author":"Vitale","year":"1998","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"11","key":"10.1016\/j.intimp.2021.107927_b0060","doi-asserted-by":"crossref","first-page":"9402","DOI":"10.1074\/jbc.M211262200","article-title":"Anthrax lethal factor proteolysis and inactivation of MAPK kinase","volume":"278","author":"Chopra","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.intimp.2021.107927_b0065","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.tranon.2015.07.001","article-title":"Phospho-MEK1\/2 and uPAR expression determine sensitivity of AML blasts to a urokinase-activated anthrax lethal toxin (PrAgU2\/LF)","volume":"8","author":"Bekdash","year":"2015","journal-title":"Transl. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2021.107927_b0070","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1074\/jbc.M116.761734","article-title":"Identification of a substrate-selective exosite within the metalloproteinase anthrax lethal factor","volume":"292","author":"Goldberg","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"22","key":"10.1016\/j.intimp.2021.107927_b0075","doi-asserted-by":"crossref","first-page":"35835","DOI":"10.18632\/oncotarget.16214","article-title":"Anti-proliferative role of recombinant lethal toxin of Bacillus anthracis on primary mammary ductal carcinoma cells revealing its therapeutic potential","volume":"8","author":"Khandia","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.intimp.2021.107927_b0080","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.jmb.2009.07.037","article-title":"The protective antigen component of anthrax toxin forms functional octameric complexes","volume":"392","author":"Kintzer","year":"2009","journal-title":"J. Mol. Biol."},{"issue":"3","key":"10.1016\/j.intimp.2021.107927_b0085","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2165\/00003088-199121030-00001","article-title":"Liposomal drug delivery","volume":"21","author":"Fielding","year":"1991","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.intimp.2021.107927_b0090","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/jps.1023","article-title":"Trends and developments in liposome drug delivery systems","volume":"90","author":"Lian","year":"2001","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2021.107927_b0095","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5665","key":"10.1016\/j.intimp.2021.107927_b0100","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1126\/science.1095833","article-title":"Drug delivery systems: entering the mainstream","volume":"303","author":"Allen","year":"2004","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.intimp.2021.107927_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-84043-w","article-title":"Novel method for screening functional antibody with comprehensive analysis of its immunoliposome","volume":"11","author":"Hamamichi","year":"2021","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.intimp.2021.107927_b0110","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.3390\/cancers13061311","article-title":"Targeting chronic myeloid leukemia stem\/progenitor cells using venetoclax-loaded immunoliposome","volume":"13","author":"Houshmand","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.intimp.2021.107927_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: a biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Exp. Hematol. Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2021.107927_b0120","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1038\/s41375-020-0760-x","article-title":"Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy","volume":"34","author":"Libert","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.intimp.2021.107927_b0125","doi-asserted-by":"crossref","DOI":"10.21037\/atm.2020.02.148","article-title":"Pre-clinical assessment of chimeric antigen receptor t cell therapy targeting CD19+ B cell malignancy","volume":"8","author":"Hu","year":"2020","journal-title":"Ann. Translat. Med."},{"issue":"6","key":"10.1016\/j.intimp.2021.107927_b0130","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/BF01741331","article-title":"Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody","volume":"32","author":"Hekman","year":"1991","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2021.107927_b0135","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021010813","article-title":"Development of CAR T-cell lymphoma in two of ten patients effectively treated with piggyBac modified CD19 CAR T-cells","author":"Bishop","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2021.107927_b0140","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.vetimm.2008.10.299","article-title":"Camelid immunoglobulins and nanobody technology","volume":"128","author":"Muyldermans","year":"2009","journal-title":"Vet. Immunol. Immunopathol."},{"issue":"8","key":"10.1016\/j.intimp.2021.107927_b0145","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1158\/0008-5472.CAN-03-3935","article-title":"Efficient cancer therapy with a nanobody-based conjugate","volume":"64","author":"Cortez-Retamozo","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2021.107927_b0150","article-title":"Development of Specific Nanobodies (VHH) for CD19 Immuno-targeting of Human B-Lymphocytes","author":"Banihahsemi","year":"2018","journal-title":"Iranian J. Basic Med. Sci."},{"key":"10.1016\/j.intimp.2021.107927_b0155","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.molimm.2018.01.010","article-title":"Liposomal nanoparticle armed with bivalent bispecific single-domain antibodies, novel weapon in HER2 positive cancerous cell lines targeting","volume":"96","author":"Nikkhoi","year":"2018","journal-title":"Mol. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2021.107927_b0160","first-page":"2085","article-title":"Preparation of CD123 mono-antibody modified tanshinone \u2161A loaded immunoliposome and its in vitro evaluation","volume":"42","author":"Wang","year":"2017","journal-title":"Zhongguo Zhong yao za zhi= Zhongguo zhongyao zazhi= China Journal of Chinese Materia Medica"},{"key":"10.1016\/j.intimp.2021.107927_b0165","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2147\/IJN.S14615","article-title":"AFM, ESEM, TEM, and CLSM in liposomal characterization: a comparative study","volume":"6","author":"Ruozi","year":"2011","journal-title":"Int. J. Nanomed."},{"issue":"24","key":"10.1016\/j.intimp.2021.107927_b0170","first-page":"6950","article-title":"Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release","volume":"60","author":"Kong","year":"2000","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.intimp.2021.107927_b0175","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2174\/1568026618666180608125344","article-title":"Improving the efficacy of anticancer drugs via encapsulation and acoustic release","volume":"18","author":"Ahmed","year":"2018","journal-title":"Curr. Top. Med. Chem."},{"issue":"2","key":"10.1016\/j.intimp.2021.107927_b0180","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0005-2736(01)00357-1","article-title":"In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach","volume":"1513","author":"Iden","year":"2001","journal-title":"Biochimica et Biophysica Acta (BBA)-Biomembranes"},{"issue":"15","key":"10.1016\/j.intimp.2021.107927_b0185","first-page":"3320","article-title":"In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma","volume":"58","author":"de Menezes","year":"1998","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.intimp.2021.107927_b0190","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1021\/nl801488u","article-title":"Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo","volume":"8","author":"Weng","year":"2008","journal-title":"Nano Lett."},{"issue":"5","key":"10.1016\/j.intimp.2021.107927_b0195","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/ijc.20880","article-title":"Potential anticancer activity of tanshinone IIA against human breast cancer","volume":"116","author":"Wang","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2021.107927_b0200","doi-asserted-by":"crossref","unstructured":"T.A. Fleisher, J.B. Oliveira, Flow cytometry, in: Clinical Immunology, Elsevier, 2019. pp. 1239\u20131251e1.","DOI":"10.1016\/B978-0-7020-6896-6.00092-2"},{"issue":"4","key":"10.1016\/j.intimp.2021.107927_b0205","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"5589","key":"10.1016\/j.intimp.2021.107927_b0210","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1126\/science.1073163","article-title":"Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition","volume":"297","author":"Park","year":"2002","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.intimp.2021.107927_b0215","doi-asserted-by":"crossref","first-page":"436a","DOI":"10.1016\/j.bpj.2018.11.2346","article-title":"Early Translocation of Anthrax Lethal Factor: Kinetics from Molecular Dynamics Simulations and Milestoning Theory","volume":"116","author":"Ma","year":"2019","journal-title":"Biophys. J."},{"issue":"5364","key":"10.1016\/j.intimp.2021.107927_b0220","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1126\/science.280.5364.734","article-title":"Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor","volume":"280","author":"Duesbery","year":"1998","journal-title":"Science"},{"issue":"19","key":"10.1016\/j.intimp.2021.107927_b0225","doi-asserted-by":"crossref","first-page":"11099","DOI":"10.1016\/S0021-9258(18)60433-8","article-title":"Internalization and processing of Bacillus anthracis lethal toxin by toxin-sensitive and-resistant cells","volume":"264","author":"Singh","year":"1989","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.intimp.2021.107927_b0230","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2174\/1567201815666181024112252","article-title":"Gemcitabine-loaded Folic Acid Tagged Liposomes: Improved Pharmacokinetic and Biodistribution Profile","volume":"16","author":"Unnam","year":"2019","journal-title":"Curr. Drug Deliv."},{"issue":"10","key":"10.1016\/j.intimp.2021.107927_b0235","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2174\/1381612822666160125114733","article-title":"Liposome-nanogel structures for future pharmaceutical applications: an updated review","volume":"22","author":"Kazakov","year":"2016","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.intimp.2021.107927_b0240","doi-asserted-by":"crossref","first-page":"381","DOI":"10.3109\/21691401.2014.953633","article-title":"Application of liposomes in medicine and drug delivery","volume":"44","author":"Daraee","year":"2016","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"16","key":"10.1016\/j.intimp.2021.107927_b0245","doi-asserted-by":"crossref","first-page":"13913","DOI":"10.1021\/acsami.7b01867","article-title":"Multiparameter Quantification of Liposomal Nanomedicines at the Single-Particle Level by High-Sensitivity Flow Cytometry","volume":"9","author":"Chen","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"1","key":"10.1016\/j.intimp.2021.107927_b0250","first-page":"3","article-title":"Antibody-Drug Conjugates: Possibilities and Challenges","volume":"11","author":"Nejadmoghaddam","year":"2019","journal-title":"Avicenna J. Med. Biotechnol."},{"issue":"20","key":"10.1016\/j.intimp.2021.107927_b0255","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.1158\/1078-0432.CCR-11-0485","article-title":"SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies","volume":"17","author":"Blanc","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2021.107927_b0260","doi-asserted-by":"crossref","unstructured":"E. Gaudio et al., A novel CD19 targeting antibody-drug conjugate, huB4-DGN462, shows promising in vitro and in vivo activity in CD19-positive lymphoma models, AACR, 2017.","DOI":"10.1158\/1538-7445.AM2017-2651"},{"issue":"5","key":"10.1016\/j.intimp.2021.107927_b0265","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.3892\/ijo.2016.3431","article-title":"Targeting the MAP kinase pathway in astrocytoma cells using a recombinant anthrax lethal toxin as a way to inhibit cell motility and invasion","volume":"48","author":"Al-Dimassi","year":"2016","journal-title":"Int. J. Oncol."},{"issue":"15","key":"10.1016\/j.intimp.2021.107927_b0270","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.1158\/0008-5472.CAN-08-0461","article-title":"Differential cellular internalization of anti-CD19 and-CD22 immunotoxins results in different cytotoxic activity","volume":"68","author":"Du","year":"2008","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.intimp.2021.107927_b0275","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1046\/j.1365-2672.1999.00893.x","article-title":"Anthrax lethal factor cleaves the N-terminus of MAPKKS and induces tyrosine\/threonine phosphorylation of MAPKS in cultured macrophages","volume":"87","author":"Vitale","year":"1999","journal-title":"J. Appl. Microbiol."},{"issue":"8","key":"10.1016\/j.intimp.2021.107927_b0280","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.bcp.2009.11.023","article-title":"Anthrax lethal toxin down-regulates type-IIA secreted phospholipase A2 expression through MAPK\/NF-\u03baB inactivation","volume":"79","author":"Raymond","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.intimp.2021.107927_b0285","first-page":"1","article-title":"Nogo-A-\u039420\/EphA4 interaction antagonizes apoptosis of neural stem cells by integrating p38 and JNK MAPK signaling","author":"Wang","year":"2021","journal-title":"J. Mol. Histol."},{"key":"10.1016\/j.intimp.2021.107927_b0290","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.coi.2020.11.006","article-title":"Inflammasome activation and evasion by bacterial pathogens","volume":"68","author":"Ta","year":"2021","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107927_b0295","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/microorganisms9010151","article-title":"Cryptosporidial Infection Suppresses Intestinal Epithelial Cell MAPK Signaling Impairing Host Anti-Parasitic Defense","volume":"9","author":"He","year":"2021","journal-title":"Microorganisms"},{"key":"10.1016\/j.intimp.2021.107927_b0300","unstructured":"Z.J. KASBO, Sensitivity of Colorectal cancer cells to the recombinant Anthrax Lethal Toxin and the Urokinase-Activated Anthrax Lethal Toxin, LEBANESE AMERICAN UNIVERSITY, 2014."},{"issue":"3","key":"10.1016\/j.intimp.2021.107927_b0305","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1042\/BJ20061891","article-title":"Manipulation of host signalling pathways by anthrax toxins","volume":"402","author":"Turk","year":"2007","journal-title":"Biochem. J"},{"issue":"1","key":"10.1016\/j.intimp.2021.107927_b0310","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.chom.2010.06.007","article-title":"Manipulation of host cell death pathways during microbial infections","volume":"8","author":"Lamkanfi","year":"2010","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.intimp.2021.107927_b0315","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1128\/IAI.72.1.430-439.2004","article-title":"Anthrax lethal toxin induces human endothelial cell apoptosis","volume":"72","author":"Kirby","year":"2004","journal-title":"Infect. Immun."},{"issue":"1","key":"10.1016\/j.intimp.2021.107927_b0320","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0006-291X(02)00227-9","article-title":"Lethal toxin of Bacillus anthracis causes apoptosis of macrophages","volume":"293","author":"Popov","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.intimp.2021.107927_b0325","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/cdd.2008.91","article-title":"Cell death in the host response to infection","volume":"15","author":"Labbe","year":"2008","journal-title":"Cell Death Differ."},{"issue":"3","key":"10.1016\/j.intimp.2021.107927_b0330","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1128\/IAI.73.3.1879-1885.2005","article-title":"GeneChip analyses of global transcriptional responses of murine macrophages to the lethal toxin of Bacillus anthracis","volume":"73","author":"Comer","year":"2005","journal-title":"Infect. Immun."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921005634?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921005634?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:29:46Z","timestamp":1761586186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921005634"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":66,"alternative-id":["S1567576921005634"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107927","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liposome-based nanocarriers loaded with anthrax lethal factor and armed with anti-CD19 VHH for effectively inhibiting MAPK pathway in B cells","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107927","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107927"}}